Home > Healthcare > Chemotherapy-Induced Myelosuppression Treatment Market
Chemotherapy-Induced Myelosuppression Treatment Market Size
Chemotherapy-Induced Myelosuppression Treatment Market size is projected to expand at a commendable rate during the forecast period of 2024-2032, owing to the increase in the overall expenditure on healthcare across the world.
The number of people suffering from leukemia is increasing, prompting medical bodies to increase the approval rate for various drugs. Cancer-related research has picked up immense pace over the past few years, with various companies working to develop best-in-class treatments and increase the patient survival rate. For example, in August 2022, Polish biotech firm Ryvu Therapeutics announced that the European Investment Bank (EIB) had provided funds worth USD 23.4 million to speed up the development of novel therapies to treat a variety of chronic blood cancers and solid tumors.
Chemotherapy-induced myelosuppression is considered one of the most common dose-limiting and fatal complications of cancer treatment. The rising incidence of a variety of cancer-related surgeries as well as chemotherapy & radiotherapy sessions.
Chemotherapy-Induced Myelosuppression Treatment Market Trends
One significant trend is the development of targeted therapies and supportive care interventions aimed at mitigating the adverse effects of chemotherapy-induced myelosuppression, such as neutropenia, anemia, and thrombocytopenia. These therapies, including growth factors, erythropoiesis-stimulating agents, and hematopoietic stem cell transplantation, are designed to boost blood cell production and enhance immune function, reducing the risk of infection and bleeding complications associated with myelosuppression.
Additionally, there is a growing emphasis on personalized medicine approaches, utilizing genetic testing and biomarker identification to tailor treatment strategies for individual patients, optimizing efficacy and minimizing side effects. The collaborations between pharmaceutical companies, research institutions, and healthcare providers are driving innovation in myelosuppression treatment, leading to the development of novel therapeutics and treatment algorithms. The significant emphasis on improving patient care and quality of life will shape the industry outlook in the coming years.
Chemotherapy-induced Myelosuppression Treatment Market Analysis
Based on drug class, the industry share from the erythropoietin stimulating agent segment is set to grow at a notable rate through 2032 with the high prevalence of anemia worldwide. The World Health Organization (WHO) has predicted that about 42% of children aged below 5 years and 40% of pregnant women suffer from anemia across the globe. These agents, apart from reducing the transfusion rate, have the ability to improve a patient’s cognition. Erythropoietin stimulating agents are also used by physicians for patients undergoing chemotherapy as they can enhance their quality of life.
As per route of administration, the injectables segment is set to register significant revenues by 2032. Injectables are becoming a vital part of the oncology field as they can mitigate the rising threat of myelosuppression. They are also gaining preference over oral medications due to better therapeutic availability. This can be attributed to the ability of this route of administration to boost the performance of a patient’s bone marrow and enhance the production of specific blood cells.
North America chemotherapy-induced myelosuppression treatment market is poised to showcase a robust increase in its valuation by 2032, attributed to the increase in R&D initiatives by pharmaceutical companies in the region. The burden of cancer is also rising in the U.S. As per the American Cancer Society, in 2022, new cancer cases in the country were predicted to reach 1.9 million. Such instances are likely to escalate the demand for chemotherapy-induced myelosuppression treatments.
Chemotherapy-Induced Myelosuppression Treatment Market Share
Some of the organizations operating in the chemotherapy-induced myelosuppression treatment industry include:
- Mission Pharmacal Company
- Janssen Pharmaceutical NV
- Mylan NV (Viatris)
- Partner TherapeuticsInc.
- Dova Pharmaceuticals (Swedish Orphan Biovitrum)
- Pfizer Inc.
- Novartis AG
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
Chemotherapy-Induced Myelosuppression Treatments Industry News
- In December 2023, Eva Pharmaceuticals and Sanofi collaborated a deal for co-developing and co-commercializing the anti-tumor necrosis factor-like ligand 1A (TL1A) therapy, TEV’574.